Abstract: The present invention relates to an antibody specific for CD47 and uses thereof, and more particularly, to an antibody that specifically binds to CD47, a chimeric antigen receptor comprising the antibody, and a pharmaceutical composition comprising the same for preventing or treating diseases mediated by CD47-expressing cells. In the present invention, antibodies that more specifically binds to CD47 were screened to establish 7 new types of antibodies (7C7, 5H4, 5A4, 4E12, 3H3, 3A5, 1E7), and it was confirm that the novel antibodies can specifically binds with CD47 antigen. In addition, since it was confirmed that the production of a chimeric antigen receptor (CAR) targeting CD47 is possible using the established antibody, the CD47-specific antibody of the present invention and the chimeric antigen receptor prepared using the same can be applied for use in preventing or treating a cancer or tumor expressing CD47.

Abstract: An antibody specific to GPC3 (Glypican 3) and uses thereof, and more particularly, to an antibody that specifically binds to GPC3, a chimeric antigen receptor comprising the antibody, a CAR-T cell expressing the chimeric antigen receptor, and a pharmaceutical composition for preventing or treating diseases mediated by cells expressing GPC3 comprising the same are provided. Antibodies that more specifically bound to GPC3 were screened to establish six novel antibodies (10E9, 8B2, 7C6, 7B9, 5E11, 1A8), and it was confirmed that the novel antibodies specifically bound to GPC3 antigen. Since it was confirmed that GPC3-CAR-T cells prepared in the present invention effectively recognized the GPC3 antigen, induced activation of the CAR-T cells, and effectively killed cells expressing GPC3, GPC3-specific antibody of the present invention, the chimeric antigen receptor prepared using the same and CAR-T cell(s) can be applied to the prevention or treatment of cancers or tumors expressing GPC3.

Abstract: The present invention relates to a humanized antibody specific for CD22 and a chimeric antigen receptor using the same, and more specifically, to a humanized antibody specifically binding to CD22, a chimeric antigen receptor including the antibody, a CAR-T cell expressing the chimeric antigen receptor, a pharmaceutical composition including the same and a method for preventing or treating a disease mediated by B cells using the pharmaceutical composition. In the present invention, it was confirmed that the CD22-CAR-T cells prepared based on a humanized antibody specifically binding to CD22 effectively recognized a CD22 antigen to activate CAR-T cells, and that the CD22-CAR-T cells effectively killed cells expressing CD22. Furthermore, the humanized antibody-based CD22-CAR-T cells specifically binding to CD22 of the present invention can be usefully utilized as a composition for preventing or treating a disease related to the expression of CD22 or a disease related to B cells.

Abstract: The present invention relates to a humanized antibody specific for CD22 and a chimeric antigen receptor using the same, and more specifically, to a humanized antibody specifically binding to CD22, a chimeric antigen receptor including the antibody or a CD19xCD22 antibody, a CAR-T cell expressing the chimeric antigen receptor, and a pharmaceutical composition including the same for preventing or treating a disease mediated by B cells. In the present invention, it was confirmed that the CD22-CAR-T cells and bispecific CD19xCD22-CAR-T cells prepared based on a humanized antibody specifically binding to CD22 effectively recognized a CD22 antigen to activate CAR-T cells, and that the CD22-CAR-T cells and bispecific CD19xCD22-CAR-T cells effectively killed cells expressing CD22.